Live Biotherapeutics Drug Discovery Services for Atopic Dermatitis
Creative Biolabs is pleased to share our cutting-edge technology and extensive expertise in the field of live biotherapeutics drug development with our customers. We offer high-quality customized services to develop well-validated and highly published next-generation probiotics (NGPs) with your bacteria-of-interest. We are building a team of talented and motivated scientists and technicians to pursue our commitment and have won a good reputation among our worldwide customers for accomplishing numerous challenging projects in this field.
Introduction to Atopic Dermatitis
Atopic dermatitis, also known as eczema, is a type of severe skin disease that can cause skin red and itchy. Atopic dermatitis can be found in each age group, but especially in children. In general, atopic dermatitis is a chronic illness that tends to flare up periodically. Pilot studies have demonstrated that atopic dermatitis can be associated with different kinds of human diseases, such as asthma or hay fever. Moreover, atopic dermatitis can be caused by a wide variety of factors, including inherited barrier defects, the dysfunction of the microbiome, and the immune system. In recent years, many biologics and drugs have been developed for treating atopic dermatitis in different populations. Among them, topical calcineurin inhibitors, antibiotics, antihistamines, and immunosuppressive agents, have become common therapeutics in clinical use. Also, NGPs have been regarded as attractive tools for atopic dermatitis management. At the same time, several novel NGP candidates derived from different beneficial bacteria strains have been exclusively studied and used for pharmaceutical applications.
Fig.1 Comparisons of traditional probiotics and Next-generation probiotics. (Lin, 2019)
NGPs for Atopic Dermatitis Treatment
Atopic dermatitis has aroused much attention due to its high incidence in children. For atopic dermatitis prevention and treatment, a new class of NGPs has been identified based on specific physiological and molecular analyses. Recent reports have indicated that a large group of bacterial species and strains may have the potential of being treated as live biotherapeutic drugs. As a world-leading service provider of NGP development, Creative Biolabs has accumulated extensive experience from the accomplishment of different projects, during which we have received many shreds of evidence on isolation, identification, and functional characterization of these bacteria.
Currently, we have also generated an atopic dermatitis-based live biotherapeutics drug discovery platform to produce novel NGPs with high safety and efficacy. Our integrated platform can be divided into more specific sub-programs based on bacterial types, including but not limited to:
Bifidobacterium lactis (B. lactis) is a gram-positive bacterium that can be used as a probiotic. B. lactis often exists in the large intestine of mammals, including humans. Evidence has shown that B. lactis plays an important role in treating various human diseases, such as malignant tumors and atopic dermatitis. For instance, B. lactis W52 has been used for enhancing host resistance to pathogens and regulating the level of interleukin in patients with atopic dermatitis. The data have revealed that B. lactis W52 may have a preventive effect on atopic eczema in children at high-risk and may be extended to 5 years old.
Lactobacillus rhamnosus (L. rhamnosus) belongs to family Lactobacillaceae. It is a non-spore gram-positive bacterium that can produce the enzyme lactase in the human body. Up to now, various kinds of L. rhamnosus strains have been isolated and regarded as effective NGPs for the treatment of atopic dermatitis. For instance, some strains of L. rhamnosus, such as L. rhamnosus GG, have proven their essential role in preclinical studies. Furthermore, several randomized double-blind studies have conducted to assess the effectiveness of L. rhamnosus NGP candidates. 120 infants have been recruited and classified into two subgroups, group A received 1x 107 colony-forming units (cfu)/g of L. rhamnosus GG, and group B is an unsupplemented group. The results have suggested that a significant improvement in skin condition has been observed in group A in comparison to group B.
Creative Biolabs has developed a fail-proof NGPs development platform for our clients all over the world. We have integrated high-quality probiotics solutions that are based in America and span the entire development chain from discovery to commercialization. Our company offers a broad range of probiotic services at a reasonable cost and with quick turnaround time. Our highly experienced scientists are ready to tackle difficult projects to meet any requirement. If you are interested in our services, please feel free to contact us for closer communication to learn how we can be involved in your project. Separate services or integrated end-to-end solutions are all welcomed.
Reference
-
Lin, T. L., et al. Investiture of next-generation probiotics on amelioration of diseases-Strains do matter. Medicine in Microecology. 2019, 1: 100002.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
Related Services
